Our previous studies reported that GA-Me targets and affect MMP2, MMP9 (11), IL-2, IFN-γ (12), caspase-9, caspase-3, STAT1, JAK1 (24), MDR1, MRP1, MRP2 (25), Bax, Bcl-2, Cyto-c (16, 25), and p53 (16, 17, 25) expression in GA-Me-treated cancer cells, implying that GA-Me might be a multitarget ligand with polypharmacological efficacy in CRC treatment (Figure 8C). This evidence concerns the gene MMP2 and colorectal carcinoma.